Most proposed mechanisms of carcinogenic progression predict that any single cell with a selective growth advantage would, by virtue of clonal expansion, provide an enlarged target for the accumulation of additional carcinogenic mutations. The relative rarity of tumor formation in organisms with billions of proliferating cells has led to the hypothesis that most cells acquiring growth advantages are selectively deleted by apoptotic mechanisms (1) . A corollary of this proposal is that suppression of the apoptotic pathway is a requirement for carcinogenesis.
Several growth factors and cytokines have been identified as suppressors of apoptosis in specific cell types (2) (3) (4) (5) . In particular, IGF I 1 has a potent ability to inhibit apoptosis in a broad range of cells (2, (5) (6) (7) (8) . The ability of the IGF I receptor to block cell death is marked in oncogene-driven cells placed in a growth factor-deprived environment and is manifested in vivo even more dramatically than in vitro (9) . Furthermore, human melanoma cells transfected with an antisense cDNA construct to the IGF I receptor were very weakly tumorigenic upon injection into nude mice compared with cells expressing wild type levels of IGF I receptors (10) . Although it was initially postulated that such IGF I receptor-deficient cells simply failed to proliferate in vivo, further analysis revealed that the cells undergo apoptosis within 27 h of injection (10) . In addition, IGF I and insulin have been demonstrated to suppress apoptosis in c-myc-induced Rat 1 fibroblasts, PC-12 cells, and IL-3-dependent hematopoietic cells (2, 3, 5) . These observations lend strong support to the notion that IGF action mediated through the IGF I receptor is directly and intimately involved in suppression of apoptosis in many cell types. If inhibition of an IGF-regulated anti-apoptotic pathway is a requisite step in carcinogenesis, then knowledge of the essential components in that pathway may lead to strategies that can specifically invoke apoptosis of transformed cells.
The IGF I receptor and insulin receptor encode homologous cytoplasmic domains (11) . In addition to a highly conserved tyrosine kinase domain, the insulin and IGF I receptor also retain homologous phosphorylation sites including sites that regulate the interaction of each receptor with the intracellular signaling proteins IRS-1 and Shc (12) (13) (14) (15) . The conservation of structure and signaling pathways shared by these related receptors explains their ability to generate similar biological responses in experimental systems (16 -20) . A primary goal in the study of insulin and IGF I receptor action is the identification of the intracellular pathways that mediate the biological actions of these hormones. One strategy to identify signaling pathways that regulate specific biological actions of insulin and IGF I receptors has been to create mutations within specific receptor sequences that disrupt one insulin or IGF I-regulated pathway while leaving others intact. Deletion mutagenesis of the insulin receptor cytoplasmic domain has generated insulin receptors with altered biological properties (21) (22) (23) (24) , suggesting that different regions of the insulin receptor cytoplasmic domain may modulate the distinct biological effects of insulin.
Analysis of the ability of mutated insulin receptors to mediate signaling in cells is obscured by the activity of endogenous insulin receptors. We have avoided this dilemma by constructing a chimeric receptor (CSF1R/IR) consisting of the extracellular ligand binding domain of the human CSF-1 receptor (25) coupled to the transmembrane and cytoplasmic domains of the human insulin receptor (26 -28) . The CSF1R/IR chimera has CSF-1-dependent enzymatic and biological properties expected of the insulin receptor and IGF I receptor (20) . CSF-1 inhibits apoptosis in CHO cells expressing the CSF1R/IR but has no protective effect on control cells. Inhibition of apoptosis by insulin in CHO cells is sensitive to the PI 3Ј kinase inhibitor wortmannin. However, deletions within the cytoplasmic domain of the CSF1R/IR that disrupt the ability of the insulin receptor cytoplasmic domain to activate MAP kinase and IRS-1-associated PI 3Ј kinase activity do not disrupt its anti-apoptotic activity. These observations indicate that the phosphorylation of IRS-1 and its subsequent association with and direct activation of PI 3Ј kinase are not requisite components of antiapoptotic signaling by the insulin receptor kinase.
EXPERIMENTAL PROCEDURES

Creation of Cell Lines Expressing the Wild Type and Mutant
CSF1R/IR Chimera-The construction of the chimera, transfection of the DNA, and isolation of clonal cell lines have been described previously (20) .
Cell Culture and Growth Factor Stimulation-CHO cells were cultured in F12 medium with 10% fetal bovine serum. Before stimulation with insulin or CSF-1 the medium was changed to serum-free medium. Insulin (100 nM) or CSF-1 (10 nM) were added to stimulate the cells.
Western Blot Analysis-Proteins were transferred to polyvinylidene difluoride membranes, and Western blots were developed using antiphosphotyrosine (PY-20, 1:1000) antibodies as specified by the manufacturer (Transduction Laboratories) or using CT-1 (1:5000) (29) antibodies. Blots were developed with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium using the appropriate secondary antibody conjugated to alkaline phosphatase.
DNA Ladder Assay-1 ϫ 10 6 cells were plated in 100-mm dishes and incubated for 18 h at 37°C in serum-free medium with or without growth factors or 5 nM staurosporine (30) . The medium from each culture dish was removed and pelleted in a bench top centrifuge for 10 min to capture any cells that had detached from the tissue culture dish. 1 ml of Hirt lysis buffer (50 mM Tris-HCl, pH 7.5, 0.6% SDS, and 10 mM EDTA) with 0.5 mg/ml proteinase K was added to each tube. The resuspended pellets were transferred back to the corresponding plate from which they were taken. The plates were incubated at 37°C for 1 h to lyse the cells. Following the incubation, 300 l of 5 M NaCl was added dropwise to each dish, and lysates were scraped into polypropylene tubes and incubated at 4°C for 4 -16 h. The precipitated lysates were centrifuged for 30 min at 31,000 ϫ g in a SS34 rotor (Sorvall). The supernatants were combined with an equal volume of isopropanol, mixed, and centrifuged for 45 min at 31,000 ϫ g in an SS34 rotor. Supernatants were immediately decanted, and the pellets were allowed to dry briefly. The pellets were resuspended in 300 l of 10 mM TrisHCl, pH 8, 1 mM EDTA containing 100 g/ml RNase A. The suspension was transferred to Eppendorf tubes and allowed to incubate at 25°C for 1 h. The DNA was extracted with an equal volume of phenol/chloroform (1:1) and precipitated, and each sample was resuspended in 100 l of DNase-free water. The DNA was radiolabeled with [␣-32 P]dATP using a kit from Trevigen (Gaithersburg, MD) and run on a 1.5% agarose gel. The gel was fixed in 10% acetic acid overnight, dried, and visualized using phosphor storage technology (Molecular Dynamics).
Quantification of Pyknotic Nuclei-Flame sterilized coverslips were placed at the bottom of 35-mm tissue culture dishes and secured with a drop of medium. 5 ϫ 10 4 CHO cells expressing CSF1R/IR or CSF1R/ IR⌬960 or transfected with the expression vector pcDNA3 (Invitrogen) were plated onto the coverslips. The day after plating the medium was replaced with fresh serum-free medium, and the cells were treated for at least 9 h at 37°C with or without 5 nM staurosporine, 1. (20) . Glucose uptake in 3T3-L1 adipocytes was measured using a modification of the method described previously (31) . 3T3-L1 adipocytes were used 14 days after induction of differentiation, at which time Ͼ90% of the cells expressed an adipocyte phenotype. Cell monolayers were washed twice with buffer A (130 mM NaCl, 2.7 mM KCl, 1 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 , 0.68 mM CaCl 2 , 0.49 mM MgCl 2 , pH 7.4) and then incubated for 2 h at 37°C in 1 ml of serum-free Dulbecco's modified Eagle's medium. To determine nonspecific glucose uptake the cells were treated for 10 min in serum-free Dulbecco's modified Eagle's medium containing 20 M cytochalasin B and 200 M phloretin. Cell monolayers were washed once with 1 ml of KRP buffer (130 mM NaCl, 5 mM KCl, 1.3 mM CaCl 2 , 1.3 mM MgSO 4 , 10 mM Na 2 HPO 4 , pH 7.4) with or without CSF-1 or insulin as indicated and incubated for 20 min at 37°C in 1 ml of the same buffer. The glucose uptake assay was initiated by replacement of KRP buffer in each well with KRP buffer containing 0.1 mM 2-deoxy-D- [2,6- 3 H] glucose (1 Ci) for 10 min at 37°C. Termination of glucose uptake was performed by the rapid removal of assay buffer followed by four rapid washes of each well with 1 ml of ice-cold buffer A containing 500 M phloretin. Cells were removed from each well with 0.4 ml of 0.1% SDS and counted for radioactivity after the addition of 4 ml of Optifluor (Packard Instrument Co.).
MAP Kinase Assay-CHO cells (1 ϫ 10 5 ) were seeded in 35-mm dishes. 16 h after plating, cells were starved in serum-free F-12 medium for 18 h. After serum deprivation, the cell monolayer was washed with PBS and stimulated with 10 nM CSF-1 or 1 M phorbol 12-myristate 13-acetate for 10 min. Cells were snap frozen with liquid nitrogen and lysed in 1 ml of lysis buffer (40 mM Tris-HCl, pH 7.4, 120 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 0.5% Triton X-100, 10 mM NaF, 10 mM sodium PP i , 10 g/ml leupeptin, 5 g/ml aprotinin), transferred to microcentrifuge tubes, and pelleted at 14,000 ϫ g for 10 min at 4°C. Clarified lysates were transferred into new microcentrifuge tubes containing 15 l of protein G-agarose beads and 10 l each of ERK-1 (C-16) and ERK-2 (C-14) antibodies (Santa Cruz Biotechnologies) and incubated for 3 h at 4°C. Immunoprecipitates were washed three times with 1 ml of lysis buffer (without sodium PP i and leupeptin) and three times with ice-cold kinase buffer (40 mM Tris-HCl, pH 7.4, 20 mM MgCl 2 , 2 mM MnCl 2 , 25 M ATP, 0.5 mM dithiothreitol). Myelin basic protein (0.5 mg/ml) and [␥-32 P]ATP (0.7 l, 10 Ci/l, and 6000 Ci/nmol) were added to each tube. After a 30-min incubation at 30°C, the reaction was stopped by adding 2ϫ sample buffer (250 mM Tris-HCl, pH 6.8, 5% SDS, 50% glycerol, 100 mM dithiothreitol) and boiling the samples for 5 min. Samples were resolved by electrophoresis on a 12% polyacrylamide gel. Each gel was stained with Coomassie Brilliant Blue to detect myelin basic protein and dried. The relative amount of 32 P incorporated into myelin basic protein was determined using phosphor storage technology (Molecular Dynamics).
In Vitro PI 3Ј Kinase Assay-CHO cells (5 ϫ 10 5 ) were seeded in 6-well plates in duplicate. The day after plating the cells were incubated in serum-free medium for 18 h. The cells were stimulated with 1 M insulin or 10 nM CSF-1 for 2 min, snap frozen with liquid nitrogen, lysed with 450 l/well of lysis buffer containing 40 mM Tris-HCl, pH 7.4, 2 mM Na 3 VO 4 , 10 mM NaF, 10 mM sodium PP i , 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 20 g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Following centrifugation for 10 min at 14,000 ϫ g, clarified lysates were incubated for 1.5-2 h at 4°C with 3 l of antibodies to IRS-1. Protein G-agarose beads (12.5 l) were added to each immune complex and precipitated for 1.5-2 h at 4°C. The immunoprecipitates were washed twice with 1% Triton X-100 and PBS, twice with 100 mM Tris-HCl, pH 7.5, and 0.5 M LiCl, and twice with 50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1 mM Na 3 VO 4 . The washed beads were resuspended in 30 l of a buffer containing (30 mM MgCl 2 , 30 nM HEPES, 0.6 mM EGTA) and left on ice. At this time the sonication mixture containing 30 mM HEPES, 0.6 mM EGTA, and 0.6 mg/ml phosphoinositol (Avanti) was prepared and placed on ice. The mixture was sonicated at 4°C for 5-7 s with a probe sonicator (Heat Systems) set at position 9, and 15 l of the sonicated mixture was added to the immunoprecipitates. [␥-
32 P]ATP (0.8 l, 10 Ci/l, 6000 Ci/nmol) was quickly added, and the mixtures were mixed rigorously at 25°C for 10 min. The reaction was stopped with 12 l of 6 M HCl and 120 l of CHCl 3 /MeOH (1:1). 20 l of the organic phase were spotted on a silica gel 60 (Merck) TLC plate that had been previously coated with 1.3% potassium oxalate in H 2 O/MeOH (3:2). Radiolabeled phospholipids were resolved in a solvent system consisting of CHCl 3 /methanol/acetone/acetic acid/H 2 O (35:13:15:12:8). The relative amount of PI 3Ј phosphate generated was determined using phosphor storage technology (Molecular Dynamics).
RESULTS
CSF-1-dependent Phosphorylation of the CSF1R/IR and CSF1R/IR⌬960 -Treatment of cells expressing the CSF1R/IR
with CSF-1 for 10 min resulted in the phosphorylation of the 170-kDa chimeric receptor (Fig. 1) . CSF-1 stimulates phosphorylation of the CSF1R/IR⌬960 to a lesser extent than it stimulates phosphorylation of the intact CSF1R/IR (Fig. 1) . The tyrosine-phosphorylated CSF1R/IR and CSF1R/IR⌬960 were immunoprecipitated with the monoclonal antibody CT-1, which is specific for the carboxyl terminus of the insulin receptor. The amounts of CSF1R/IR and CSF1R/IR⌬960 in each cell line were equal as determined by a Western blot using the CT-1 antibody (Fig. 1) , thus showing that the difference in tyrosine phosphorylation between the CSF1R/IR and the CSF1R/IR⌬960 is due to the 12-amino acid deletion of the juxtamembrane domain that is present in the CSF1R/IR⌬960 and not to clonal variation.
Inhibition of DNA Fragmentation by CSF-1 in Cells Expressing the CSF1R/IR-CHO cells expressing the CSF1R/IR were examined for their ability to resist apoptosis upon treatment with CSF-1. Cells were incubated with CSF-1 (0.1-10 nM) for 1 h and then induced to undergo apoptosis with the addition of 5 nM staurosporine. Cells treated with staurosporine for 9 h showed the presence of DNA fragmentation (Fig. 2) . CSF-1 decreased DNA fragmentation in a dose-dependent manner.
The Effects of a Juxtamembrane Deletion on Anti-apoptotic Signaling by the CSF1R/IR-The juxtamembrane region contains an important phosphorylation site at Tyr 960 (32) that facilitates tyrosine phosphorylation of IRS-1 and Shc by the insulin receptor kinase (12) (13) (14) . Deletion of 12 amino acids within the juxtamembrane domain (⌬960) of the insulin receptor or the CSF1R/IR blocks the ability of the insulin receptor tyrosine kinase to phosphorylate IRS-1 or Shc (20, 33). To determine whether or not the anti-apoptotic signaling of the CSF1R/IR required juxtamembrane phosphorylation sites, we looked at the ability of the CSF1R/IR⌬960 to protect cells from staurosporine-induced apoptosis. Cells transfected with the expression vector alone, expressing the CSF1R/IR, or expressing the CSF1R/IR⌬960 were treated with 5 nM staurosporine and with or without 10 nM CSF-1 or 1.7 M insulin for 18 h at 37°C. The percentage of pyknotic nuclei present was determined as a measure of the level of apoptosis. Cells transfected with the expression vector alone contained detectable pyknotic nuclei after a 9-h treatment with staurosporine alone (Fig. 3) . Physiological concentrations of IGF I inhibit apoptosis in different cultured cell lines (2) . Previous studies have demonstrated that CHO cells express relatively low numbers (1,000 -10,000 receptors/cell) of insulin receptors and are relatively insensitive to physiological concentrations of insulin. High concentrations of insulin were used to ensure activation of endogenous IGF I receptors. Insulin blocked the formation of pyknotic nuclei upon staurosporine treatment, whereas 10 nM CSF-1 had no effect (Fig. 3) . Cells expressing the CSF1R/IR were also susceptible to staurosporine-induced apoptosis in the absence of insulin or CSF-1. When insulin or CSF-1 were present, the number of pyknotic nuclei detected was greatly reduced (Fig.  3) . Cells expressing the CSF1R/IR⌬960 were also protected from staurosporine-induced death by insulin or CSF-1.
The Effects of a Juxtamembrane Deletion on Stimulation of Glucose Uptake by the CSF1R/IR-The CSF1R/IR and the CSF1R/IR⌬960 were compared for their ability to stimulate glucose uptake in 3T3-L1 adipocytes. Saturating concentrations of insulin (100 nM) stimulated [ 3 H]2-deoxyglucose uptake 8 -9-fold in adipocytes expressing either chimera (Fig. 4) . 10 nM CSF-1 is sufficient to maximally activate the CSF1R/IR kinase (20) . Adipocytes expressing the CSF1R/IR were also able to increase glucose uptake approximately 7.7-fold in response to 10 nM CSF-1 (Fig. 4) . In contrast, the juxtamembrane deletion severely inhibited the ability of CSF-1 to stimulate glucose uptake in cells expressing the CSF1R/IR⌬960 (Fig. 4) .
Regulation of MAP Kinase Activation by the Juxtamembrane Region of the Insulin Receptor Cytoplasmic Domain-IRS-1
and Shc are important mediators of insulin-induced Ras activation and the subsequent activation of MAP kinases (34 -36) . We tested the ability of the 12-amino acid deletion in the CSF1R/IR to affect CSF-1-induced activation of MAP kinases in CHO cells. CHO cells transfected with the expression vector alone activated MAP kinases approximately 3.5-fold in response to phorbol esters but were unresponsive to CSF-1 (Fig.  5) . In cells expressing the CSF1R/IR, CSF-1 was able to activate MAP kinases at least as well as phorbol esters (Fig. 5) . The 12-amino acid juxtamembrane deletion (⌬960) blocked the ability of CSF-1 to stimulate the MAP kinases but had no effect on the action of phorbol esters (Fig. 5) . The Effect of PI 3Ј Kinase Inhibition on the Anti-apoptotic Action of the Insulin Receptor-PI 3Ј kinase has been shown to play a role in inhibiting apoptosis in some cells (3, 37) . The contribution of PI 3Ј kinase activity to anti-apoptotic signaling of the insulin receptor kinase in CHO cells was tested with the PI 3Ј kinase inhibitor wortmannin. CHO cells expressing the human insulin receptor were treated with 5 nM staurosporine with or without 1 M wortmannin and 100 nM insulin for 18 h. Wortmannin alone had no effect on the extent of apoptosis in staurosporine-treated cells (Fig. 6) . Insulin significantly reduced the number of pyknotic nuclei detectable upon staurosporine treatment (Fig. 6) . However, the addition of wortmannin significantly reversed the anti-apoptotic effect of insulin (Fig. 6) .
The Effect of Carboxyl-terminal Truncation on the Anti-apoptotic Action of the CSF1R/IR-PI 3Ј kinase can be activated through association with phosphorylated IRS-1 and to a lesser extent with the phosphorylated carboxyl terminus of the insulin receptor (38 -40) . We examined anti-apoptotic signaling in cells expressing the CSF1R/IR⌬CT, which contains a 43-amino acid truncation of the carboxyl terminus of the chimera or cells expressing the CSF1R/IR⌬960⌬CT, which combines the carboxyl-terminal truncation with the juxtamembrane deletion. Cells expressing the mutated forms of the chimera were treated for 18 h at 37°C with 5 nM staurosporine and with or without 100 nM insulin or 10 nM CSF-1. Cells expressing the CSF1R/ IR⌬CT showed resistance to apoptosis in the presence of insulin or CSF-1, reducing the level of pyknotic nuclei approximately 3-and 4-fold when treated with insulin or CSF-1, respectively (Fig. 7) . Cells expressing the CSF1R/IR⌬960⌬CT also showed resistance to staurosporine-induced apoptosis in the presence of insulin or CSF-1, reducing pyknotic nuclei formation approximately 8-and 4-fold, respectively (Fig. 7) . However, the anti-apoptotic action of the CSF1R/IR⌬960⌬CT was reversed by the addition of wortmannin (Fig. 7 ). These data demonstrate that although activation of PI 3Ј kinase may be essential to the anti-apoptotic action of the insulin receptor kinase, the loss of PI 3Ј kinase binding sites from the carboxyl terminus does not appear to impair the anti-apoptotic activity of the insulin receptor cytoplasmic domain.
Activation of PI 3Ј Kinase by Intact and Mutated Chimeric
Receptors-PI 3Ј kinase is activated by association with proteins phosphorylated on tyrosine by the insulin receptor kinase (38) . We examined whether or not cells expressing the CSF1R/ IR, the CSF1R/IR⌬960, or the CSF1R/IR⌬960⌬CT could activate PI 3Ј kinase associated with tyrosine phosphorylated pro- teins in general and IRS-1 in particular. Serum-starved cells expressing the CSF1R/IR, CSF1R/IR⌬960, or CSF1R/ IR⌬960⌬CT were treated with 10 nM CSF-1 and 1 M wortmannin for 10 min. The cells were lysed and immunoprecipitated with antibodies to phosphotyrosine. Analysis of PI 3Ј kinase activity in the immunoprecipitates revealed that the CSF1R/IR strongly stimulated PI 3Ј kinase activity in cells treated with CSF-1 (Fig. 8A ). Simultaneous treatment with wortmannin blocked the activation of PI 3Ј kinase by the CSF1R/IR. Deletion of the juxtamembrane domain also severely impaired the ability of the CSF1R/IR⌬960 to activate PI 3Ј kinase associated with tyrosine phosphorylated proteins (Fig. 8A) . Wortmannin treatment removed the small CSF-1 stimulated increase in PI 3Ј kinase activity bound to tyrosine phosphorylated proteins in cells expressing the CSF1R/IR⌬960. The additional deletion of the carboxyl-terminal tail in the CSF1R/IR⌬960⌬CT completely abolished the ability of CSF-1 to activate PI 3Ј kinase bound to tyrosine phosphorylated proteins (Fig. 8A) . This observation suggests that a small portion of PI 3Ј kinase activity associated with tyrosine phosphorylated proteins was associated with tyrosine phosphorylation sites within the carboxyl terminus of the chimeric receptor.
IRS-1 is a major substrate and signaling intermediate of the insulin receptor kinase (41) . PI 3Ј kinase activity was assayed in IRS-1 immunoprecipitates from CHO cells expressing the CSF1R/IR or the CSF1R/IR⌬960. Insulin stimulated PI 3Ј kinase activity 5-fold in CHO cells expressing the CSF1R/IR and 10-fold in CHO cells expressing the CSF1R/IR⌬960 (Fig. 8B) . Treatment with 10 nM CSF-1 caused an 18-fold activation of PI 3Ј kinase associated with IRS-1 from cells expressing the CSF1R/IR. In contrast, CSF-1 did not significantly stimulate PI 3Ј kinase activity associated with IRS-1 in CHO cells express- ing the CSF1R/IR⌬960 (Fig. 8B ). These data demonstrate that the juxtamembrane region within the insulin receptor cytoplasmic domain is required for the activation of PI 3Јkinase associated with IRS-1.
DISCUSSION
We have used a chimeric receptor consisting of the extracellular domain of the CSF-1 receptor and the transmembrane and cytoplasmic domains of the insulin receptor to study antiapoptotic signaling mechanisms of the insulin receptor cytoplasmic domain. The anti-apoptotic properties of the insulin receptor cytoplasmic domain were examined by deletion of structures within the receptor that couple it to known intracellular mediators of insulin action. Our data demonstrate that a deletion within the receptor juxtamembrane domain that inhibits the phosphorylation of IRS-1 and Shc by the insulin receptor (33) and the CSF1R/IR (20) also suppresses glucose transport (Fig. 4) , MAP kinase activation (Fig. 5) , and the activation of PI 3Ј kinase associated with IRS-1 (Fig. 8) . However, the same juxtamembrane deletion does not suppress antiapoptotic signaling by the CSF1R/IR (Fig. 3) . The observation that wortmannin treatment reverses the anti-apoptotic actions of insulin on staurosporine-treated CHO cells supports previous data indicating that PI 3Ј kinase activity is an important component of the survival pathway (3, 37) . However, experiments with mutated chimeric receptors (Figs. 7 and 8) indicate that neither the activation of PI 3Ј kinase associated with the insulin receptor kinase nor the activation of PI 3Ј kinase associated with other tyrosine phosphorylated proteins is a critical mediator of insulin-generated anti-apoptotic signals. These observations suggest that the activation of PI 3Ј kinase by the insulin receptor cytoplasmic domain to inhibit apoptosis can occur by other as yet unidentified mechanisms.
CSF-1 activates the insulin receptor kinase within the CSF1R/IR chimera in a time-and dose-dependent manner characteristic of the intact insulin receptor (20) . Furthermore, CSF-1-stimulated phosphorylation of the CSF1R/IR in intact cells mimics the pattern of phosphorylation of the intact insulin receptor (20) . The ability of the CSF1R/IR to inhibit apoptosis (Fig. 3) or stimulate glucose transport (Fig. 4) is probably not due to the formation of hybrid receptors formed between the CSF1R/IR and endogenous insulin or IGF I receptors. The levels of IGF I receptors in CHO cells are too low to readily detect hybrid formation in the CHO cells studied. However, previous experiments (20) demonstrated that there was no cross-phosphorylation between the insulin receptor and the CSF1R/IR when both receptors were expressed to high levels in CHO cells or in 3T3-L1 cells. These data argue against hybrid formation between the CSF1R/IR and endogenous IGF I receptors in CHO cells.
The 12-amino acid deletion within the juxtamembrane domain of the CSF1R/IR blocks the ability of the chimeric receptor to stimulate glucose uptake (Fig. 4) but does not impair the ability of CSF1R/IR to inhibit apoptosis (Fig. 3) or stimulate adipogenesis (20) . These data suggest that the juxtamembrane region including Tyr 960 plays a critical role in the ability of the insulin receptor cytoplasmic domain to stimulate glucose uptake.
The ⌬960 mutation also disrupts the ability of the CSF1R/IR to interact with and phosphorylate IRS-1 (20) , which is required for the subsequent activation of PI 3Ј kinase (38) . Experiments in IRS-1 Ϫ/Ϫ mice have suggested that IRS-1 contributes to the activation of insulin-stimulated glucose transport (42, 43) . Data from other laboratories also suggest that PI 3Ј kinase activation is an important component of insulin-stimulated glucose transport (44, 45) . However, recent experiments have suggested that mere activation of PI 3Ј kinase is not sufficient to induce glucose uptake because the activation of PI 3Ј kinase associated with IRS-1 by IL-4 in transfected L6 cells is not sufficient to mimic the effects of insulin (46) . Similarly, agents that inhibit the function of IRS-1 have been shown to block some biologic effects of insulin without impairing its ability to stimulate glucose uptake (47, 48) . Our data suggest that the ability of the insulin receptor kinase to stimulate glucose uptake requires the insulin receptor juxtamembrane domain. However, disruption of that domain may inhibit its interaction with other substrates in addition to IRS-1, each of which is capable of contributing to insulinstimulated glucose transport. Related signaling molecules IRS-2 (49), IRS-3 (50), and IRS-4 (51) are all potential candidates. These data further suggest that the ability of PI 3Ј kinase to mediate a specific biological effect is context-dependent. Thus, activation of PI 3Ј kinase bound to IRS proteins may be relevant to glucose uptake only in the context of IRS protein interaction with and phosphorylation by the insulin receptor kinase. Conversely, PI 3Ј kinase bound to IRS-1 may not be an essential transducer of the anti-apoptotic effects of the lipid kinase if it is not proximal to the relevant mediator of the survival pathway.
IRS-1 and Shc couple the insulin receptor kinase to mechanisms that activate Ras and its downstream effectors (34 -36) . Consistent with the inability of the CSF1R/IR⌬960 to phosphorylate IRS-1 and Shc (20) , this mutated chimera is unable to significantly activate MAP kinases (Fig. 5) . Although it is possible that imperceptible amounts of IRS-1 and/or Shc phosphorylation is catalyzed by the CSF1R/IR⌬960, these data suggest that the phosphorylation of IRS-1 and Shc by the chimera is not essential for transduction of survival signals from the insulin receptor kinase.
Previous reports conflict regarding a role for MAP kinases in anti-apoptotic signaling within different cell types. Our observations are supported by previous experiments in UV-treated Rat 1 fibroblasts (37) and serum-starved primary sympathetic neurons (52) in which the MAP ERK kinase inhibitor PD098059 (53) failed to block IGF I-mediated inhibition of UV-induced apoptosis. Similarly, survival in undifferentiated PC12 cells was found to be unaffected by inhibition of the MAP kinase pathway by dominant-negative RasN17 (3). Furthermore, the ability of the oncogene v-abl to suppress apoptosis in an IL-3-dependent mast cell line was concomitant with the phosphorylation of Shc but independent of activation of MAP kinases (54) . These results contrast to observations in which IGF I-mediated survival of differentiated PC12 cells was blocked by PD098059 (55) . The ability of an activated MAP ERK kinase 1 transgene to suppress apoptosis in differentiated PC12 cells also supports a role for MAP kinase in anti-apoptotic signaling in these cells. Taken together, these data suggest that the viability of some cell types may be dependent on an intact MAP kinase pathway. However, our data suggest that activation of the MAP kinase pathway by growth factor receptors may not be required to generate anti-apoptotic signals.
Inhibition of apoptosis by PI 3Ј kinase is believed to be mediated, at least in part, through the activation of the kinase Akt by PI 3Ј phospholipids (37, 56, 57) . We also examined the role of PI 3Ј kinase in the insulin-stimulated, anti-apoptotic signaling pathway by treatment of CHO cells with insulin, staurosporine, and the PI 3Ј kinase inhibitor wortmannin. Wortmannin was able to significantly reverse insulin-mediated inhibition of apoptosis (Fig. 6) . However, the poor stability of wortmannin in aqueous solution and the long time course of the pyknotic nuclei assay (9 -18 h) required use of a high concentration of the fungal metabolite. The high (1 M) concentration of wortmannin used in these experiments may not be specific for PI 3Ј kinase. Thus, the ability of wortmannin to reverse the anti-apoptotic effect of insulin (Fig. 6 ) and CSF-1 in cells expressing the CSF1R/IR⌬CT (Fig. 7) could also be due to its action on other enzymes. Nevertheless, our data are consistent with previous reports that PI 3Ј kinase activity is a necessary component of anti-apoptotic signaling (3, 37) . PI 3Ј kinase is primarily activated by the insulin receptor through its association with tyrosine phosphorylated IRS-1 (38) . PI 3Ј kinase activity can also be activated through direct association of the lipid kinase with the carboxyl terminus of the insulin receptor cytoplasmic domain (39, 40) . We tested the anti-apoptotic activity of the CSF1R/IR⌬CT, which contains a truncation of 43 amino acids from the carboxyl terminus. The carboxyl-terminal truncation removes the tyrosine phosphorylation sites to which PI 3Ј kinase can bind directly (40) . The carboxyl-terminal deletion alone had no deleterious effect on the anti-apoptotic signaling properties of the CSF1R/IR⌬CT (Fig. 7) . In combination with the juxtamembrane deletion, the deletion also inhibited apoptosis (Fig. 7) but completely blocked the activation of PI 3Ј kinase associated with tyrosine phosphorylated proteins (Fig. 8) . These data indicate that the activation of PI 3Ј kinase activity bound directly to the insulin receptor cytoplasmic domain or bound to other tyrosine phosphorylated intracellular proteins is not essential for the inhibition of apoptosis.
The ⌬960 mutation disrupted the ability of the chimeric receptor to activate PI 3Ј kinase associated with IRS-1 (Fig. 8) but did not affect anti-apoptotic signaling by the insulin receptor cytoplasmic domain (Fig. 3) . These data suggest that PI 3Ј kinase activity associated with IRS-1, in contrast to its reported contribution to insulin-stimulated glucose uptake, is also not essential for the inhibition of apoptosis by the insulin receptor kinase. Furthermore, these data imply that as yet undetermined intracellular mechanisms may activate PI 3Ј kinase to transmit survival signals from the insulin receptor cytoplasmic domain. Potential mediators of the survival signal may include other members of the IRS family (49 -51) . However, the presence of phosphotyrosine binding domains within each of these related proteins predicts that the ability of all IRS proteins to mediate signaling by the insulin receptor kinase may be dependent upon interaction with the juxtamembrane region of the insulin receptor cytoplasmic domain. PI 3Ј kinase may also be activated independent of its association with tyrosine phosphorylated proteins. Interaction of the p110 catalytic subunit of PI 3Ј kinase with Ras activates its lipid kinase (58, 59) and can inhibit apoptosis (60) . The inability of the CSF1R/IR to phosphorylate IRS-1 or Shc (20) , stimulate glucose uptake, or activate MAP kinases (Fig. 5) implies that PI 3Ј kinase is not activated through Ras by this mutated chimera. However, the possibility exists that PI 3Ј kinase might also be activated through an unidentified member of the Ras superfamily or another unknown protein.
Our observations indicate that the juxtamembrane domain and 43 amino acids of the carboxyl-terminal tail are dispensable for anti-apoptotic signaling by the insulin receptor kinase. However, mutation of Tyr 1251 or mutation of His 1293 and Lys 1294 within the cytoplasmic domain of the IGF I receptor abolished the anti-apoptotic action of IGF I (61), suggesting that structures within the cytoplasmic tail of this receptor might be required for inhibition of apoptosis. These amino acids within the IGF I cytoplasmic domain are not conserved within the homologous insulin receptor carboxyl-terminal tail, but they flank a region conserved between the IGF I receptor and insulin receptor in which one-third of the amino acids are acidic. Deletion of this acidic region with the remainder of the carboxyl-terminal tail did not prevent the anti-apoptotic functions of IGF I (61). Thus, structures conserved between the insulin receptor and IGF I receptor kinase that regulate antiapoptotic signaling have yet to be identified. Inhibition of apoptosis by the IGF I receptor is dependent on an active tyrosine kinase (61) . Taken together, these observations and the data presented here suggest that a novel cytoplasmic substrate may transduce the anti-apoptotic signals of the insulin and IGF I receptor kinase.
